U.S. Markets closed

Novacyt S.A. (NVYTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
4.1800+0.4800 (+12.97%)
At close: 1:03PM EDT

Novacyt S.A.

Watchmoor Point
Unit 1 Watchmoor Road
Camberley GU15 3AD
United Kingdom
44 1276 600 081

Full Time Employees110

Key Executives

NameTitlePayExercisedYear Born
Mr. Graham MullisCEO & DirectorN/AN/A1963
Mr. Anthony DyerCFO, Company Sec. & DirectorN/AN/AN/A
Ms. Lisa HenrietGroup Operations DirectorN/AN/AN/A
Ms. Mandy CowlingCorp. & Investor Relations Mang.N/AN/AN/A
Ms. Wendy KarbanGroup HR Mang.N/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, and commercialization of clinical diagnostic products for cancer and infectious diseases in Africa, Europe, the Asia Pacific, the United States, and the Middle East. The company operates through Corporate and Diagnostics, and Molecular Products segments. The Corporate and Diagnostics segment manufactures and distributes reagents and kits for bacterial and blood tests. The Molecular Products segment designs, manufactures, and distributes test kits for various diseases in humans, animals, and food products. The company's diagnostic products are used in oncology, microbiology, haematology, and serology testing. It also develops, manufactures, and distributes diagnostic products for food laboratories; and manufactures and supplies reagents and tests for in vitro diagnostic tests and blood grouping applications under the Plasmatec and Biotec brand names. The company has collaboration with AstraZeneca, GSK, and the University of Cambridge to support increase testing for COVID-19. It serves universities, hospitals, clinics, and testing laboratories. Novacyt S.A. was founded in 2006 and is headquartered in Camberley, the United Kingdom.

Corporate Governance

Novacyt S.A.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.